Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > 0.50$ by 2026 if they get the approval

<< Previous

Bullboard Posts

Next >>

Post by DONOOWon Dec 07, 2021 5:31pm

317 Views

Post# 34208283

0.50$ by 2026 if they get the approval

Global sales are only estimated to be ~$200M cumulative by 2026. One of the members of the one Facebook groups made a forecast of SP with MC. Looking like ~$0.50 per share if the company can have a $500M MC with the current dilution.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments